Summary & Overview
HCPCS Level II J0650: Injection, Levothyroxine Sodium, 10 mcg
HCPCS Level II code J0650 designates a 10 mcg injectable formulation of levothyroxine sodium, used for thyroid hormone replacement when parenteral administration is required. This code matters nationally as it captures utilization and billing for an alternative route of thyroid hormone therapy in acute care and outpatient infusion settings, affecting pharmacy and medical benefit adjudication.
Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for injectable levothyroxine, the typical sites of service where this code is used, and payer coverage considerations. The publication summarizes common billing and coding themes, relevant benchmarks where available, and notes on policy or coverage guidance that influences claim adjudication for injectable thyroid replacement.
The analysis identifies where J0650 is most applicable clinically—patients unable to take oral levothyroxine—and outlines what billing staff and policy analysts should expect to find in payer rules and prior authorization pathways. Data not available in the input are explicitly noted where relevant.
Billing Code Overview
HCPCS Level II code J0650 represents an injection of levothyroxine sodium, not otherwise specified, 10 mcg. The service involves administration of a thyroid hormone replacement formulation in an injectable form intended for patients needing parenteral levothyroxine.
Service type: Injectable medication administration
Typical site of service: Outpatient clinic or hospital inpatient setting where injectable medications are administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 56-year-old woman with a history of hypothyroidism secondary to Hashimoto thyroiditis presents to the outpatient endocrinology clinic due to difficulty tolerating oral levothyroxine after recent gastrointestinal surgery that impaired absorption. The clinician determines that temporary parenteral thyroid hormone is medically necessary. The patient receives an intramuscular injection of levothyroxine sodium, J0650 (10 mcg), administered by a licensed nurse in the clinic. Vital signs and thyroid function tests (TSH, free T4) are reviewed before administration. The workflow includes verification of medication, informed consent, preparation of the injectable dose, injection administration, observation for immediate adverse reaction for 15–30 minutes, documentation of lot number and expiration, and scheduling follow-up for repeat dosing or transition back to oral therapy once absorption improves.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no special circumstance applies |
| 22 | Increased procedural services | Use when complexity or time for preparation/administration significantly exceeds typical for J0650 |